{
    "organizations": [],
    "uuid": "c7d35e6f8b57d251f8a1ce34c4997d826ac3915f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/bioverativ-ma-sanofi-fr/sanofi-near-deal-to-buy-bioverativ-for-more-than-11-5-bln-wsj-idUSL2N1PH029",
    "ord_in_thread": 0,
    "title": "Sanofi near deal to buy Bioverativ for more than $11.5 bln -WSJ",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 21 (Reuters) - Sanofi SA is said to be near a deal to buy drug maker Bioverativ Inc for more than $11.5 billion, the Wall Street Journal reported, citing people familiar with the matter.\nThe deal, which could be announced as soon as Monday, would value Bioverativ at about $105 a share, the Journal reported. ( on.wsj.com/2mYJulp ) Sanofi and Bioverativ were not immediately available for comment outside regular business hours.\nReporting by Shubham Kalia in Bengaluru; Editing by Paul Simao\n ",
    "published": "2018-01-22T09:46:00.000+02:00",
    "crawled": "2018-01-22T20:41:16.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "sanofi",
        "sa",
        "said",
        "near",
        "deal",
        "buy",
        "drug",
        "maker",
        "bioverativ",
        "inc",
        "billion",
        "wall",
        "street",
        "journal",
        "reported",
        "citing",
        "people",
        "familiar",
        "matter",
        "deal",
        "could",
        "announced",
        "soon",
        "monday",
        "would",
        "value",
        "bioverativ",
        "share",
        "journal",
        "reported",
        "sanofi",
        "bioverativ",
        "immediately",
        "available",
        "comment",
        "outside",
        "regular",
        "business",
        "hour",
        "reporting",
        "shubham",
        "kalia",
        "bengaluru",
        "editing",
        "paul",
        "simao"
    ]
}